Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 8:59 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Sleep Initiation and Maintenance Disorders
Interventions: zolpidem tartrate, sodium oxybate, Matching Placebos; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Stanford, California

Conditions: Generalized Anxiety Disorder
Interventions: ENX-102, Placebo; Drug
Lead sponsor: Engrail Therapeutics INC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 32
States / cities: Phoenix, Arizona • Garden Grove, California • Imperial, California + 29 more

Conditions: Dementia, Alzheimer's Type, Alzheimer's Disease
Interventions: SAR448851, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 14
States / cities: Long Beach, California • Oakland, California • Naples, Florida + 11 more

Conditions: Pain
Interventions: VX-548, Moxifloxacin, Moxifloxacin Placebo, VX-548 Placebo; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Conditions: Obesity
Interventions: Galantamine, Placebo Oral Capsule, Intralipid, Heparin; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: COVID-19 Infection
Interventions: Brequinar, Placebo; Drug
Lead sponsor: Clear Creek Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Homewood, Alabama • Long Beach, California • Doral, Florida + 11 more

Conditions: Healthy
Interventions: ZD03, Placebo; Drug · Other
Lead sponsor: Shanxi Zhendong Leading Biotechnology Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Alzheimer's Disease
Interventions: MK-1167, Donepezil, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Hallandale, Florida • Decatur, Georgia • Savannah, Georgia

Conditions: Carcinoid Syndrome
Interventions: Telotristat etiprate, Octreotide LAR Depot, Placebo; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 9
States / cities: Little Rock, Arkansas • San Francisco, California • Indianapolis, Indiana + 6 more

Conditions: EBV Viremia, CMV Viremia
Interventions: Valganciclovir, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: Canagliflozin 50 mg, Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Heart Failure
Interventions: Sodium reduction, omega 3 and lycopene supplements, rice bran oil capsules, Generic dietary feedback from; Behavioral · Dietary Supplement
Lead sponsor: Terry Lennie; Other
Eligibility: 21 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Lexington, Kentucky • Louisville, Kentucky

Conditions: Gastroduodenal Ulcer
Interventions: Naproxen, Aspirin, Celecoxib, Clopidogrel, Placebo; Drug
Lead sponsor: Research Associates of New York, LLP; Other
Eligibility: 18 Years to 75 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: AZD 8529, Risperidone, Placebo to match AZD8529, Placebo to match risperidone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Garden Grove, California • Glendale, California • Rockville, Maryland

Conditions: Acute Pain, Chronic Pain, Knee Pain Chronic, Neuropathic Pain
Interventions: Venlafaxine 37.5 MG, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Bioequivalence
Interventions: Pharmaceutical-lipid aspirin (PL-ASA); Drug
Lead sponsor: PLx Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Opioid Sensitivity, Individual Difference, Abuse Opioids
Interventions: Within-subject test of blinded study medication; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Periodontitis, Periodontal Diseases, Periodontal Pocket
Interventions: Amoxicillin, Metronidazole, Placebo; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 35 Years and older
Enrollment: 236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Relapsing Multiple Sclerosis
Interventions: Ozanimod, Placebo; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 6
States / cities: Berkeley, California • Fresno, California • Sacramento, California + 3 more

Conditions: Multiple Sclerosis, Secondary Progressive
Interventions: dimethyl fumarate, Placebo; Drug · Other
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 58 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 7
States / cities: Long Beach, California • San Francisco, California • Tampa, Florida + 4 more

Conditions: Insomnia
Interventions: Defined CBD, Placebo; Drug
Lead sponsor: Defined Research; Industry
Eligibility: 25 Years to 70 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Stress Disorders, Post-Traumatic
Interventions: Brexpiprazole, Sertraline, Brexpiprazole Matching Placebo, Sertraline Matching Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 54
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more

Conditions: Stem Cell Surveillance
Interventions: Placebo, Chaga Mushroom, Ginseng extract, Olive extract, Potassium Hydrogen Glucarate; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Aripiprazole, Placebo Capsule, Placebo Tablet; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Xyrem(Sodium Oxybate) and Ambien(Zolpidem Tartrate) in the Treatment of Chronic Insomnia.

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease

A Study to Evaluate the Effect of VX-548 on the QT/QTc Interval in Healthy Participants

Racial Differences in Vagal Control of Glucose Homeostasis

CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

ZD03 Capsule Study

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients

A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus

Nutrition Intervention to Decrease Symptoms in Patients With Heart Failure

Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on the Healing of Stomach and Intestinal Ulcers

Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients

The Use of Venlafaxine in Reducing Pain in Primary Total Knee Replacement

Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.

A118G SNP and OPRM1 Gene Opioid-Mediated Effects in Humans

Shaping the Indications for Periodontal Adjunctive Antibiotics in Dental Practice

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

Evaluation of an Oral Cannabidiol (CBD)-Terpene Formulation on Sleep Physiology in Participants With Insomnia

A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)

Rapid Response of Stem Cells and Immune Cells for Efficacy

Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression